Statistics for Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer
Total visits
| views | |
|---|---|
| Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer | 77 |
Total visits per month
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 1 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| Shukla2021Association-AAM.pdf | 218 |
| java.util.UUID:4f6c6119-d633-4fd4-8d57-d8d3f08474da | 97 |
| java.util.UUID:1310c5f9-858f-4749-a224-454c57a18996 | 14 |
| java.util.UUID:3a658d32-5502-4af1-9fcf-d0511803a793 | 5 |
Top country views
| views | |
|---|---|
| United States | 63 |
| China | 2 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 36 |
| Fairfield | 8 |
| Ann Arbor | 4 |
| Cambridge | 3 |
| Houston | 3 |
| San Francisco | 3 |
| Lake Mary | 1 |
| Seremban | 1 |
| White Plains | 1 |